We performed a systematic review and meta-analysis of the literature regarding
cardiovascular outcomes of differentiated thyroid cancer (DTC) patients who are on long …

Purpose The primary aim was to study the risk of cardiovascular mortality in patients with
differentiated thyroid carcinoma (DTC). Secondary aims were to evaluate all-cause mortality …

TSH-suppressive therapy and the increased risk of cardiovascular disease in patients with
differentiated thyroid cancer (DTC) was previously reported. A recent study by Pajamäki and …

Differentiated thyroid cancer is the most common form of thyroid cancer and its prognosis is
favourable in most cases. Suppression of thyroid stimulating hormone (TSH) by supra …

Surgery—with or without postoperative radioiodine—is the standard of care for most patients
with differentiated thyroid carcinoma (DTC). Thyroid hormone replacement therapy is the …

Objectives Thyroid hormone suppression therapy has been widely used in the treatment of
thyroid cancer, but concerns have been raised about the cardiovascular risks of this …

Background: Long-term management of intermediate-and high-risk differentiated thyroid
cancer (DTC) involves thyrotropin (TSH) suppression with thyroid hormone to prevent …

Treatment and follow-up of patients affected by differentiated thyroid cancer (DTC) has
evolved over the last years. The initial single treatment approach for all patients 1, 2 has …

Objective To investigate the relationship between TSH suppression therapy and
cardiovascular events in patients with thyroid cancer after surgery. Methods Pub Med, Web …

The ideal therapy for differentiated thyroid cancer is uncertain. Although thyroid hormone
treatment is pivotal, the degree of thyrotropin (TSH) suppression that is required to prevent …